The expression of p53, p16 proteins and prevalence of apoptosis in oral squamous cell carcinoma. Correlation with mode of invasion grading system

Saudi Medical Journal

Volumn 25, Issue 12, 2004, Pages 1922-1930

  Tokman, Benay ^a   Gultekin, Sibel E ^a   Sezer, Cem ^b   Alpar, Reha ^c  

^a GAZI UNIVERSITY   (Turkey)

^b Mediterranean University   (Turkey)

^c HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

FORMALDEHYDE; PROTEIN P16; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER GRADING; CANCER INHIBITION; CANCER INVASION; CARCINOGENESIS; CLINICAL ARTICLE; CORRELATION ANALYSIS; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIP CARCINOMA; MALE; MOUTH CARCINOMA; NICK END LABELING; PATHOGENESIS; PREDICTION; PREVALENCE; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE; TURKEY (REPUBLIC);

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU NICK-END LABELING; LIP NEOPLASMS; MALE; MIDDLE AGED; MOUTH MUCOSA; MOUTH NEOPLASMS; NEOPLASM INVASIVENESS; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 13844275796     PISSN: 03795284     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Bryne M. Prognostic value of various molecular and cellular features in oral squamous cell carcinomas: a review. J Oral Pathol Med 1991: 20: 413-420.
2. Anneroth G, Hansen LS. A methodologic study of histologic classification and grading of malignancy in oral squamous cell carcinoma. Scand J Dent Res 1987: 92: 448-468.
3. Yamamoto E, Miyakawa A, Kohama G. Mode of invasion and lymph node metastasis in squamous cell carcinoma of the oral cavity. Head Neck Surg 1984: 6: 938-947.
4. Bryne M, Koppang H, Lilleng R, Kjaerheim A. Malignancy grading of the deep invasive margins of oral squamous cell carcinomas has high prognostic value. J Pathol 1992; 166: 375-381.
5. Girod SC, Pfeiffer P, Reis J, Pape HD. Proliferative activity and loss of function of tumor suppressor genes as biomarkers in diagnosis and prognosis of benign and preneoplastic oral lesions and oral squamous cell carcinoma. Brit J Oral Max Surg 1998: 36: 252-260.
6. Partridge M, Kiguwa S, Emilion G, Pateromickelakis, Hern RA. New insights into P53 protein stabilisation in oral squamous cell carcinoma. Oral Oncology 1999: 35: 45-55
7. Bandoh N, Hayashi T, Kishibe K, Takahara M, Imada M, Nonaka S et al. Prognostic value of p53 mutations, bax and spontaneous apoptosis in maxillary sinus squamous cell carcinoma. Cancer 2002: 94: 1968-1980.
8. Boyle JO, Hakim J, Koch W, Ruppert JM, Sidransky D. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 1993: 53: 4477-4480.
9. Van Der Riet P, Nawroz H, Hruban RH, Cario R, Tokino K, Koch W. Frequent loss of chromosome 9p21-22 early in head and neck cancer progression. Cancer Res 1994: 54: 1156-1158.
10. Langdon JD, Partridge M. Expression of the tumor suppressor gene P53 in oral cancer. Brit J Oral Max Surg 1992: 30: 214-220.
11. Ahomadegbe JC, Barrois M, Fogel S, Le Bihan ML, Douc-Rasy S, Duvillard P et al. High incidence of P53 alterations in head and neck primary tumor and metastasis; absence of correlation with clinical outcome. Frequent protein overexpression in epithelium and in early noninvasive lesions. Oncogene 1995: 10: 1217-1227.
12. Akanuma D, Uzawa N, Yoshida MA, Negishi A, Amagasa T, Ikeuchi T. Inactivation patterns of the p16 gene in oral squamous cell carcinoma cell lines. Oral Oncol 1999: 35: 476-483.
13. Okamoto A, Demetric DJ, Spillare EA, Hagiwara K, Hussain SP, Bennet WP et al. Mutations and altered expression of p16INK4 in human cancer. Proc Natl Acad Sci USA 1994: 91: 11045-11049.
14. Merlo A, Herman JG, Mao L, lee D, Gabrielson E, Burger PC et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995: 1: 686-692.
15. Cairns P, Polascik TJ, Eby Y, Tokino K, Galifano J, Merlo A. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet 2001: 11: 210-212.
16. Shintani S, Nakahara Y, Mihara M, Ueyama Y, Matsumura T. Inactivation of the p14 ARF, p15 INK4B and p16 INK4A genes is a frequent event in human oral squamous cell carcinomas. Oral Oncol 2001: 37: 498-504.
17. Warnakulasuriya K, Tavassoli M, Jhonson NW. Relationship of P53 overexpression to other cell cycle regulatory proteins in oral squamous cell carcinoma. J Oral Pathol Med 1998; 27: 376-381.
18. Reed AL, Califano J, Cairns P, Wertra WH, Jones RM, Koch W et al. High frequency of p16 inactivation in head and neck squamous cell carcinoma. Cancer Res 1996; 56: 3630-3633.
19. Schoelch ML, Le QT, Silverman S, McMillan A, Dekker NP, FU KK et al. Apoptosis associated proteins and the development of oral squamous cell carcinoma. Oral Oncol 1999: 35: 77-85.
20. Itakura M, Mori S, Park NH, Bonavida B. Both HPV and carcinogen contribute to the development of resistance to apoptosis during oral carcinogenesis. Int J Oncol 2000; 16: 591-597.
21. Lipponen PK, Aaltomoa S. Apoptosis in bladder cancer as related to to standard prognostic factors and prognosis. J Pathol 1994: 173: 333-339.
22. King ED, Matteson J, Jacobs SC, Kyprianou N. Incidence of apoptosis, cell proliferation and bcl-2 expression in transitional cell carcinoma of the bladder: association with tumor progression. J Urol 1996; 155: 316-320.
23. Guerry M, Vabre L, Talbot M, Mamelle G, Lendant AM, Hill C et al. Prognostic value of histological and biological markers in pharyngeal squamous cell carcinoma: a case control study. Br J Cancer 1998: 77: 32-36.
24. Kapranos N, Stathopoulos GP, Monolopuolos L, Kokka E, Papadimitriou CON, Bibas A et al. P53, p21 and p27 protein expression in head and neck cancer and their prognostic value. Anticancer Res 2001; 21: 521-528.
25. Koontongkaew S, Chareonkitkajorn L, Chanvitan A, Leelakriangsak M, Amornphimoltham P. Alterations of P53, Rb, cyclin D1 and cdk4 in human oral and pharyngeal squamous cell carcinomas. Oral Oncol 2000; 36: 334-339.
26. Ng IOL, Lam KY, Ng M, Regezi JA. Expression of p21/waf1 in oral squamous cell carcinoma-correction with P53 and mdm2 and cellular proliferation index. Oral Oncol Europ J Cancer 1999; 35B: 63-69.
27. White D, Broton CE, Shilitoe EJ. The unexplained survival of cells in oral cancer: what is the role of p53. J Oral Pathol Med 2002; 31: 125-133.
28. Sionov RV, Haupt Y. Apotosis by P53 mechanism, regulation and clinical implication. Springer Semin Immunpathol 1998; 19: 345-362.
29. Nylander K, Dabalsteen E, Hall PA. The p53 molecule and its prognostic role in squamous cell carcinomas of head and neck. J Oral Pathol Med 2000; 29: 413-425.
30. Shin DM, Lee JS, Lippman SM, Lee JU, Tu ZN, Choi G, et al. p53 expression: predicting recurrence and second primary tumors in head and neck squamous cell carcinoma. J Natl Cancer Inst 1996; 88: 519-529.
31. Narayama A, Vaughan AT, Gunaratne S, Kathuria S, Walter SA, Reddy SP. Is P53 an independent prognostic factor in patients with laryngeal carcinoma? Cancer 1998; 82: 286-291.
32. Gapany M, Pavelic ZP, Gapany SR, Pavelic L, Li YG, Crawen JM et al. Relationship between immunohistochemically detectable p53 protein and prognostic factors in head and neck tumors. Cancer Detect Prev 1993; 17: 379-386.
33. Nylander K, Schildt EB, Eriksson M, Roos G. PCNA, Ki67, p53, bcl-2 and prognosis in intraoral squamous carcinoma of the head and neck. Analyt Cell Pathol 1997; 14: 101-110.
34. Piffko J, Bankfalvi A, Tory K, Fuzesi L, Bryne M, Ofner D et al. Molecular assessment of p53 abnormalities at the invasive front of oral squamous cell carcinoma. Head Neck 1998: 20: 8-15.
35. Koch VM, Brennan JA, Zahurak M, Goodman SN, Westra WH, Schwab D et al. p53 mutations and locoregional treatment failure in head and neck squamous cell carcinoma. J Natl Cancer Inst 1996; 88: 1580-1586.
36. Homma E, Furuta Y, Oridate N, Nakona Y, Kohashi G, Yagi K et al. Prognostic significance of clinical parameters and biological markers in a patient with squamous cell carcinoma of the head and neck treated with concurrent chemoradiotherapy. Clin Cancer Res 1999; 5: 801-806.
37. Kannan K, Munirajan AK, Krishnamurty J. The p16/p19 gene mutations are infrequent and are mutually exclusive to P53 mutations in Indian oral squamous cell carcinoma. Int J Oncol 2000; 16: 585-590.
38. Heinzel PA, Balaram P, Bernard HU. Mutations and polymorphism in the p53, p21 and p16 genes in oral carcinomas of Indian betel qoud chewers. Int J Cancer 1996; 68: 420-423.
39. Gruttgen A, Reichenzeller M, Junger M, Schlien S, Affolter A, Bosch FX. Detailed gene expression analysis but no microsatellite marker analysis of 9p21 reveals differential defects in the INK4A gene locus in the majority of the head and neck cancers. J Pathol 2001; 194: 311-317.
40. Ambosch P, Schlott T, Hilmes D, Ruschenburg I. p16 alterations and retinoblastoma protein expression in squamous cell carcinoma and neighboring dysplasia from the upper aerodigestive tract. Virchows Arch 2001: 438: 343-349.
41. Caldas C, Hahn SA, Da Costa LT, Redston MS, Schutte M, Seymour AB et al. Frequent somatic mutations and homozygot deletions of p16 gene in pancreatic adenocarcinoma. Net Genet 1994; 8: 27-32.
42. Saito T, Nakajima T, Mogi K. Immunohistochemical analysis of cell cycle associated proteins p16, pRb, p53, p27 and Ki 67 in oral cancer and precancer with special reference to verrucous carcinomas. J Oral Pathol Med 1999; 28: 226-232.
43. Klaes R, Friedrich T, Spitkowsky D, Ridder R, Rudy W, Petry U et al. Overexpression of p16 (INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of cervix uteri. Int J Cancer 2001; 92: 276-284.
44. Klussmann JP, Gultekin SE, Weissenborn SJ, Weiland U, Dries V, Dienes HP et al. Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papilloma virus. Am J Pathol 2003; 162: 747-773.
45. Naresh KN, Lakshminarayanan K, Pai SA, Borges AM. Apoptosis index is a predictor of metastatic phenotype in patients with early stage squamous carcinoma of the tongue. Cancer 2001; 91: 578-584.
46. Lipponen P, Aaltomaa S, Kosma VM, Syrjanen K. Apoptosis in breast cancer as related to histopathological characteristics and prognosis. Eur J Cancer 1994; 30A: 2068-2073.
47. Hindermann W, Berndt A, Wunderlich H, Katenkamp D, Kosmehl H. Quantitative evaluation of apoptosis and proliferation in renal cell carcinoma. Correlation to tumor subtype, cytological grade according to thionase-classification and the occurrence of metastasis. Pathol Res Pract 1991; 193: 1-7.
48. Mc Menamin ME, O'Neill AJ, Gaffney EF. Extent of apoptosis in overian serous carcinoma : relation to mitotic and proliferative indices, p53 expression and survival. Mol Pathol 1997: 50: 242-246.
49. Aihara M, Scardino PT, Truong LD, Wheeler TM, Goad JR, Yang G et al. The frequency of apoptosis correlates with the prognosis of Gleason grade 3 adenocarcinoma of the prostate. Cancer 1995: 75: 522-529.
50. Levine EL, Renehan A, Gossiel R, Davidson SE, Roberts SA, Chadwick C et al. Apoptosis, intrinsic radiosensitivity and prediction of radiotherapy response in cervical carcinoma. Radiother Oncol 1995; 37: 1-9.
51. Ito Y, Matsuura N, Sakon M, Takedo T, Umeshita K, Nagano H et al. Both cell proliferation and apoptosis significantly predict shortened disease-free survival in hepatocellular carcinoma. Br J Cancer 1999; 81: 747-751.
52. Xie X, Clausen OP, De Angelis P, Boysen M. The prognostic value of spontaneous apoptosis, bax, bcl-2 and p53 in oral squamous cell carcinoma of the tongue. Cancer 1999; 86: 913-920.